Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis: The aim of this study was to evaluate the impact on metabolic control of periodic use of a 5-day fasting-mimicking diet (FMD) programme as an adjunct to usual care in people with type 2 diabetes under regular primary care surveillance. Methods: In this randomised, controlled, assessor-blinded trial, people with type 2 diabetes using metformin as the only glucose-lowering drug and/or diet for glycaemic control were randomised to receive 5-day cycles of an FMD monthly as an adjunct to regular care by their general practitioner or to receive regular care only. The primary outcomes were changes in glucose-lowering medication (as reflected by the medication effect score) and HbA 1c levels after 12 months. Moreover, changes in use of glucose-lowering medication and/or HbA 1c levels in individual participants were combined to yield a clinically relevant outcome measure (‘glycaemic management’), which was categorised as improved, stable or deteriorated after 1 year of follow-up. Several secondary outcome measures were also examined, including changes in body weight. Results: One hundred individuals with type 2 diabetes, age 18–75 years, BMI ≥27 kg/m 2, were randomised to the FMD group (n=51) or the control group (n=49). Eight FMD participants and ten control participants were lost to follow-up. Intention-to-treat analyses, using linear mixed models, revealed adjusted estimated treatment effects for the medication effect score (−0.3; 95% CI −0.4, −0.2; p<0.001), HbA 1c (−3.2 mmol/mol; 95% CI −6.2, −0.2 and −0.3%; 95% CI −0.6, −0.0; p=0.04) and body weight (−3.6 kg; 95% CI −5.2, −2.1; p<0.001) at 12 months. Glycaemic management improved in 53% of participants using FMD vs 8% of control participants, remained stable in 23% vs 33%, and deteriorated in 23% vs 59% (p<0.001). Conclusions/interpretation: Integration of a monthly FMD programme in regular primary care for people with type 2 diabetes who use metformin as the only glucose-lowering drug and/or diet for glycaemic control reduces the need for glucose-lowering medication, improves HbA 1c despite the reduction in medication use, and appears to be safe in routine clinical practice. Trial registration: ClinicalTrials.gov NCT03811587 Funding: The project was co-funded by Health~Holland, Top Sector Life Sciences & Health, the Dutch Diabetes Foundation and L-Nutra. Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that short cycles of very-low-calorie intake, such as those used in FMDs, can lead to decreases in fat mass while preserving lean mass, improved physical performance, and glucoregulation”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [230]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They often use periodic, proprietary 5-day protocols using meal replacements which can be convenient, but potentially prohibitively expensive for patients”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [230]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Changes in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012
Effects of intermittent fasting on health, aging, and disease
de Cabo, R., & Mattson, M. P. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1905136 · Cited by 1,605 · cited 1×
“Fasting evokes evolutionarily conserved adaptive hormonal and cellular responses that enhance stress resistance, dampen inflammation and optimise metabolism [1].”
BackgroundLim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164 · cited 1×
“Limiting dietary intake to approximately 3560 kJ/day (850 kcal/day) for 12–20 weeks, followed by structural support for weight loss maintenance, facilitates disease remission in people with type 2 diabetes [8–10].”
BackgroundLean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017 · cited 1×
“Limiting dietary intake to approximately 3560 kJ/day (850 kcal/day) for 12–20 weeks, followed by structural support for weight loss maintenance, facilitates disease remission in people with type 2 diabetes [8–10].”
BackgroundMaintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876
Brandhorst, S., Choi, I. Y., Wei, M., Cheng, C. W., Sedrakyan, S., Navarrete, G., Dubeau, L., Yap, L. P., Park, R., Vinciguerra, M., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.012 · Cited by 850
Self-citation
Cited by
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“They often use periodic, proprietary 5-day protocols using meal replacements which can be convenient, but potentially prohibitively expensive for patients [230].”
Metadata
- Authors
- van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., van den Akker-van Marle, E. M., Lamb, H. J., Longo, V. D., Numans, M. E., & Pijl, H.
- Affiliations
- Leiden University Medical Center (NL)
- University of Southern California (US)
- ORCID
- Venue
- Diabetologia
- Published
- 2024-03-28
- Volume
- 67
- Issue
- 7
- Pages
- 1245-1259
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC11153305
- OpenAlex
- W4393258687
- Cited by
- 25
- References
- 32
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Funders
- L-Nutra
- Diabetes Fonds
- Health~Holland
- Topics
- Health Sciences › Medicine › Physiology (medical) › Dietary Effects on Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- fasting-mimicking diet, type 2 diabetes, glycemic control, HbA1c, metformin, primary care, body weight, intermittent fasting, weight loss, metabolic control, cost-effectiveness, quality of life
- MeSH terms
- Glycemic Control, Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Primary Health Care, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-024-06137-0
- The paper
- van den Burg, E. L., Schoonakker, M. P., van Peet, P. G., van den Akker-van Marle, E. M., Lamb, H. J., Longo, V. D., Numans, M. E., & Pijl, H. (2024). Integration of a fasting-mimicking diet programme in primary care for type 2 diabetes reduces the need for medication and improves glycaemic control: a 12-month randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-024-06137-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.